Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
To drive anabolic processes, epithelial ovarian cancer (EOC) is heavily reliant on the tricarboxylic acid (TCA) cycle and oxidative phosphorylation.
Lung cancer affects approximately 48,500 persons in the United Kingdom every year. New treatments are urgently needed because only around 20% of patients live 5 years after diagnosis, and it is the leading cause of cancer death.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
Researchers are rushing to review a group of bacteria known as actinomycetes, which are one of the most successful sources of treatment.
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.
Ovarian cancer is a difficult to diagnose malignancy that is often caught at a more advanced stage. Treatments for this cancer have changed little over the past few decades, with surgery and chemotherapy being the most common therapeutic approaches.
Porvair Sciences will exhibit its latest assay kits and microplates for cancer and life science research at the American Association for Cancer Research (AACR) meeting in New Orleans, USA from the 8th – 13th April 2022.
The prognosis for ovarian cancer patients is grim: less than half of high-grade serous ovarian cancer (HGSC) patients survive past five years from diagnosis. Initially, the tumors typically respond well to chemotherapy but become resistant after repeated treatments, enabling the cancer to regrow.
Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.
A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.
Cancer cells sometimes develop resistance to the cytotoxic drugs used in chemotherapy. Figuring out why the treatment isn't working and why it may even defeat its own purpose is therefore important to understand.
Recent research disclosed that around half of the people who refused to receive secondary genomic findings switched opinions after their healthcare provider presented them with further information.
Researchers have used sophisticated imaging technology to offer unmatched insights into the BRCA1-BARD1 protein complex.
In the evolving field of cancer biology and treatment, innovations in organ-on-a-chip microdevices allow researchers to discover more about the disease outside the human body.
A protein involved in making cells move offers a clue to how certain types of cancer metastasize and develop into secondary tumors, according to new research from the University of Warwick.
Chronic alcohol abuse and hepatitis can injure the liver and lead to fibrosis, the buildup of collagen and scar tissue. As a potential approach to treating liver fibrosis, University of California San Diego School of Medicine researchers and their collaborators are looking for ways to stop liver cells from producing collagen.
Even on a good day, DNA is constantly getting damaged. Nicks, scratches, breaks: the delicate strands that carry life's genetic code take a beating as they jumble about in the course of their work. If left untreated, errors accumulate, with fatal consequences -- such as cancerous tumors -- for the cell and the organism.
An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn's Perelman School of Medicine.
A new study finds breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, which appears in CANCER, states that compared to the general population in the United States, the risk of new cancer diagnoses among survivors was 20% higher for those with hormone receptor (HR) positive cancers and 44% higher for those with HR-negative cancers.
Modified immune cells that ruthlessly kill cancerous tumors may prove a game-changer for people living with late-stage cancer.